Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma

Overview of attention for article published in Journal of Clinical Investigation, June 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (88th percentile)
Above-average Attention Score compared to outputs of the same age and source (64th percentile)

Mentioned by

news: 1 news outlet
twitter: 5 X users

patent: 4 patents

Readers on

mendeley: 62 Mendeley

So far, Altmetric has seen 5 X posts from 5 X users, with an upper bound of 70,805 followers.

NEK2 and USP7 inhibitors show pre-clinical efficacy in inhibiting #myeloma cell growth and overcoming NEK2-induced and -acquired drug (including proteasome inhibitor) resistance in xenograft mouse models: https://t.co/Kmcj66lbhY. https://t.co/5HIDmSDHd4

RT @jclinicalinvest: Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma https://t.co/Q1dOUXrYXu @IowaMed…

Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma https://t.co/Q1dOUXrYXu @IowaMed #hematology https://t.co/U0eoDTftJz

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 1 additional X posts.